Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 357

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 357
---
      Transfer from collaboration liabilities      December 31, 2024  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Monalizumab                  5,155                 ( 4,404)      ( 536)                                                     215  
  Sanofi options               2,500                               —                                                        2,500  
  Sanofi services              2,826                 ( 2,100)      —                                                          726  
  Total                       10,483                 ( 6,504)      ( 536)                                                          

(3) Of which € 616 2,825

13.2) Government financing for research expenditures

The Company receives grants from the European Commission and the French government and state organizations in several different forms:

•Investment and operating grants; and

• Research Tax Credits.

The total amount for government financing for research expenditures recorded as other income in the income statement can be analyzed as follows:

                                                      Year ended December 31,                                                       
  (in thousands of euro)                                                 2022                 2023                 2024             
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Research Tax Credit(1)                                                           7,925                9,729                7,463  
  Grant and other tax credit (2)                                          110                 —                      25             
  Government financing for research expenditures                                   8,035                9,729                7,488  

(1) As of December 31, 2024, the amount is composed of the research tax credit calculated and recognized for the 2024 financial year for an amount of € 7,463 9,800 9,167 1,270

F-78

14)Operating expenses

  (in thousands of euro)                                      Year ended December 31,                                                                                      
                                                                             2022 (1)                                      2023                        2024                
                                                                                 R& D          G& A         Total          R& D          G& A          R& D          G& A  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Subcontracting costs (1)                                                                        —                                         —                           —  
  Cost of supplies and consumable materials                                  ( 3,051)        ( 531)      ( 3,582)      ( 2,611)        (